Intracoronary Injection of CD34-Cells in Chronic Ischemic Heart Failure: 7 Years Follow-Up of the DanCell Study

Morten Hansen, Sebastian Nyby, Jacob Eifer Møller, Lars Videbæk, Moustapha Kassem, Torben Barington, Per Thayssen, Axel Cosmus Pyndt Diederichsen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


Objectives: Seven years ago, the DanCell study was carried out to test the hypothesis of improvement in left ventricular ejection fraction (LVEF) following repeated intracoronary injections of autologous bone marrow-derived stem cells (BMSCs) in patients suffering from chronic ischemic heart failure. In this post hoc analysis, the long-term effect of therapy is assessed. Methods: 32 patients [mean age 61 (SD ± 9), 81% males] with systolic dysfunction (LVEF 33 ± 9%) received two repeated intracoronary infusions (4 months apart) of autologous BMSCs (1,533 ± 765 × 10(6) BMSCs including 23 ± 11 × 10(6) CD34(+) cells and 14 ± 7 × 10(6) CD133(+) cells). Patients were followed for 7 years and deaths were recorded. Results: During follow-up, 10 patients died (31%). In univariate regression analysis, the total number of BMSCs, CD34(+) cell count and CD133(+) cell count did not significantly correlate with survival (hazard ratio: 0.999, 95% CI: 0.998-1.000, p = 0.24; hazard ratio: 0.94, 95% CI: 0.88-1.01, p = 0.10, and hazard ratio: 0.96, 95% CI: 0.87-1.07, p = 0.47, respectively). After adjustment for baseline variables in multivariate regression analysis, the CD34(+) cell count was significantly associated with survival (hazard ratio: 0.90, 95% CI: 0.82-1.00, p = 0.04). Conclusions: Intracoronary injections of a high number of CD34(+) cells may have a beneficial effect on chronic ischemic heart failure in terms of long-term survival. © 2014 S. Karger AG, Basel.

Udgave nummer2
Sider (fra-til)69-74
StatusUdgivet - 12. aug. 2014

Fingeraftryk Dyk ned i forskningsemnerne om 'Intracoronary Injection of CD34-Cells in Chronic Ischemic Heart Failure: 7 Years Follow-Up of the DanCell Study'. Sammen danner de et unikt fingeraftryk.